Efficacy and safety of once-weekly semaglutide vs daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): A double-blind, phase 3b, randomized controlled trial
The Lancet Diabetes & Endocrinology Oct 25, 2019
Lingvay I, Catarig AM, Frias JP, et al. - In a double-blind, parallel-group, phase 3b, randomized controlled trial carried out at 111 centers in 11 countries on 788 individuals at least 18 years old who had uncontrolled T2DM on stable daily metformin therapy, experts contrasted the efficiency and safety of semaglutide (a GLP-1 receptor agonist) with canagliflozin (an SGLT2 inhibitor) in individuals with T2DM. Patients were randomized to semaglutide 1·0 mg (n = 394) or canagliflozin 300 mg (n = 394). In decreasing HbA1c and body weight od individuals with T2DM uncontrolled on metformin therapy, once-weekly semaglutide 1·0 mg was found out to be outperforming the daily canagliflozin 300 mg. Thus, these results may escort treatment intensification decisions.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries